Cleveland Clinic Partners with Owlstone Medical to Establish New Center
Published on 15 Oct 19, under Breath Biopsy, Cancer, Cardiovascular & metabolic disease
Cleveland Clinic is partnering with Owlstone Medical to establish a new Center for Early Disease Detection. The Center will investigate measuring and quantifying volatile organic compounds (VOCs) from exhaled breath – in combination with other non-invasive biomarkers from other bodily fluids such as saliva and blood – for the early detection of multiple diseases from chronic conditions to cancer.
Cleveland Clinic is committed to providing patients with the best care available and this starts with accurately diagnosing disease as early as possible. Breath is emerging as a promising approach to early disease detection based on its ease of sample collection and potential to offer high levels of sensitivity, and so Cleveland Clinic has chosen to collaborate with Owlstone Medical to establish the Center.
The Center’s first study will focus on identifying VOCs in breath that can be utilized as biomarkers for the early detection of multiple forms of liver disease and to distinguish between them. Visit our blog to read more about VOCs biomarkers of liver diseases and why breath testing is such a promising medium for liver disease detection.
Read the full announcement of Centre for Early Disease Detection on the Cleveland clinic website.